Leerink downgraded Boundless Bio (BOLD) to Market Perform from Outperform with a price target of $3, down from $15. The company is discontinuing current monotherapy and combination arms of BBI-355 in the Phase 1/2 POTENTIATE clinical trial based on a narrow therapeutic index observed with dosing, the analyst tells investors in a research note. The firm is moving to the sidelines pending validation of Boundless Bio’s new approach. It removed all value for the CHK1 program until the company validates the BBI-355 and BBI-825 combination hypothesis in specific tumor types.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLD:
- Boundless Bio Announces Major Workforce Reduction Strategy
- Boundless Bio discontinuing BBI-355 and BBI-825 programs
- Positive Outlook for Boundless Bio Inc. Driven by Promising Pipeline Developments and Strong Financial Position
- Boundless Bio reports Q1 EPS (71c) vs ($12.27) last year
- Boundless Bio files $400M mixed securities shelf